Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 010,84 pts
-0.87%


Last updated : 20/11/2026 - 09h28
🏠 Home   ➤    Stock news

GenSight Biologics closes its approximately €2 million fundraising with Invus and Heights Capital

The transaction, announced on November 20, 2026, was subscribed by two existing shareholders, Invus and Heights Capital, and completes the fundraising carried out in October 2026.

The biotech company, which develops gene therapies for neurodegenerative diseases of the retina, is still awaiting structural funding for its RECOVER phase 3 trial.


GenSight Biologics closes its approximately €2 million fundraising with Invus and Heights Capital

A runway aligned with the first payments of the RECOVER trial

The net proceeds of the transaction amount to approximately €1.05 million. They will be used to finance operating activities and working capital requirements, in addition to revenues from early access programs.

The financing runway corresponds to the timing of the first significant payments related to the preparation of the RECOVER trial. It remains contingent on the number of patients treated under the French named-patient early access program (AAC) being in line with the company's estimates.

The cash flow projections do not include any exercise of the warrants issued in connection with this transaction. If all of them were exercised, GenSight Biologics would receive approximately €0.93 million in additional gross proceeds.

Chief Financial Officer Jan Eryk Umiastowski stated: “With this financing, we have completed, on schedule, the fundraising of approximately €2 million that we announced with our half-year results.” According to him, the renewed commitment of the two investors allows the company to “approach our upcoming discussions with regulatory authorities with confidence.”

7% discount, 60-month warrants and dilution of non-participating shareholders

The transaction took the form of a capital increase with waiver of preferential subscription rights, with no priority period, under a structure similar to the financings of March and October 2026. It covers 4,237,288 new shares, 13,157,898 pre-funded warrants and 17,395,186 share subscription warrants.

The issue price of €0.0708 per share with one warrant represents a nominal discount of 7% to the closing price on November 19, 2026, of €0.0761. The exercise price of the warrants, i.e. €0.0913 per share, represents a 20% premium to this price, and the warrants are exercisable for 60 months.

The share capital will comprise 250,454,618 shares after the issue, and up to 272,310,109 in the event all warrants are exercised. A shareholder holding 1% of the capital and not having participated would see its stake fall to 0.98%, then to 0.90% after exercise of all warrants, on a non-diluted basis.

On a diluted basis, Invus will hold 24.4% of the capital, compared with 21.5% before the transaction, and Heights Capital 18.3%, compared with 17.9%. The 4,237,288 ordinary shares issued in connection with the transaction are expected to be admitted to trading on Euronext Paris on November 24, 2026, without lock-up commitment. Shares resulting from the exercise of the warrants will be admitted later, as they are issued.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: -1,2 millions d'euros
  • Quarterly revenue: -1,2 millions d'euros
  • Net income: -10,3 millions d'euros
Guidance from the release
  • « Based on its current cash position and projected cash flows, the Company's available financial resources are not sufficient to cover its operating requirements over the next twelve months. »
Risks mentioned
  • Incertitude significative relative à la continuité d'exploitation et besoin de financement structurel de 16 millions d'euros avant fin mars 2027
  • Calendrier de réalisation des traitements dans les programmes d'accès dérogatoires imprévisible
  • Dépendance vis-à-vis du financement pour démarrer l'essai RECOVER au second semestre 2027
Opportunities identified
  • Encaissements de 6,5 millions d'euros générés par les programmes d'accès dérogatoires payants
  • Réduction du besoin net de trésorerie opérationnelle de 37 % à 1,6 million d'euros grâce aux revenus des programmes d'accès
  • Transfert technologique de fabrication réussi chez Catalent permettant une reproductibilité du procédé

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours